Tilsotolimod

Unassigned

New Medicines

Refractory malignant melanoma - in combination with ipilimumab

Information

New molecular entity
Idera Pharmaceuticals
Idera Pharmaceuticals

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials
Yes

Category

Toll-like receptor 9 (TLR9) agonist. Activation of TLR9 results in a cascade that induces effects of endogenous interferon-alpha and other immune response factors.[2,3]
The UK incidence of malignant melanoma is about 21 per 100,000 people, and is doubling every 10-20 years. [1]
Refractory malignant melanoma - in combination with ipilimumab
Intradermal